PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of iaiPermissionsJournals.ASM.orgJournalIAI ArticleJournal InfoAuthorsReviewers
 
Infect Immun. Feb 2007; 75(2): 666–676.
Published online Nov 21, 2006. doi:  10.1128/IAI.01280-06
PMCID: PMC1828486
Intranasal Vaccination with a Secreted Chlamydial Protein Enhances Resolution of Genital Chlamydia muridarum Infection, Protects against Oviduct Pathology, and Is Highly Dependent upon Endogenous Gamma Interferon Production[down-pointing small open triangle]
Ashlesh K. Murthy,1 James P. Chambers,1 Patricia A. Meier,2 Guangming Zhong,3 and Bernard P. Arulanandam1*
Department of Biology, South Texas Center for Emerging Infectious Diseases, University of Texas at San Antonio, San Antonio, Texas 78249,1 Department of Pathology, Wilford Hall Medical Center, San Antonio, Texas 78236,2 Department of Microbiology and Immunology, University of Texas Health Science Center, San Antonio, Texas 782293
*Corresponding author. Mailing address: Department of Biology, University of Texas at San Antonio, 6900N Loop 1604W, San Antonio, TX 78249. Phone: (210) 458 5492. Fax: (210) 458 5523. E-mail: Bernard.arulanandam/at/utsa.edu.
Received August 9, 2006; Revised September 26, 2006; Accepted November 6, 2006.
There is currently no licensed vaccine against Chlamydia trachomatis, the leading cause of sexually transmitted bacterial disease worldwide. Conventional vaccination attempts using surface-exposed chlamydial antigens have achieved only partial success. We have employed a novel vaccination strategy using a secreted protein, chlamydial protease-like activity factor (CPAF), which has been shown to degrade host major histocompatibility complex transcription factors and keratin-8 and therefore may allow immune evasion and establishment of a productive infection. Intranasal immunization using recombinant CPAF (rCPAF) plus interleukin-12 (IL-12) (rCPAF+IL-12 immunization) was used to assess the protective immunity against genital Chlamydia muridarum infection in BALB/c mice. rCPAF+IL-12 immunization induced robust gamma interferon (IFN-γ) production and minimal IL-4 production by splenocytes upon in vitro recall with rCPAF. The total and immunoglobulin G2a (IgG2a) anti-rCPAF antibody levels in serum were significantly elevated after rCPAF+IL-12 vaccination, as were the total antibody, IgG2a, and IgA levels in bronchoalveolar lavage and vaginal fluids when the animals were compared to animals that received rCPAF alone. rCPAF+IL-12-vaccinated mice displayed significantly reduced bacterial shedding upon chlamydial challenge and accelerated resolution of infection compared to mock-immunized (phosphate-buffered saline) animals. Moreover, rCPAF+IL-12-immunized animals exhibited protection against pathological consequences of chlamydial infection, including the development of hydrosalpinx and oviduct dilatation. This vaccination regimen also reduced the development of fibrosis and the influx of neutrophils into the upper genital tract when the animals were compared to mock-immunized (phosphate-buffered saline) animals after bacterial challenge. rCPAF+IL-12-mediated resolution of the bacterial infection and protection against Chlamydia-induced inflammatory disease were highly dependent on endogenous IFN-γ production. Together, these results demonstrate that secreted chlamydial antigens may be novel vaccine candidates to induce protective immunity.
Chlamydia trachomatis is the leading cause of sexually transmitted bacterial disease worldwide (8). Despite the availability of potent antimicrobial drugs, the majority of genital chlamydial infections are initially asymptomatic and thus not treated (8, 31). Left untreated, chlamydial infections induce immunopathology in the uterus and fallopian tubes, causing pelvic inflammatory disease and complications such as ectopic pregnancy and infertility (8, 25, 56, 57). Additionally, short-lasting natural immunity against chlamydial infections and nontreatment of affected sexual partners result in high reinfection rates (25). The incidence of genital tract chlamydial infections is highest in women at the peak of their reproductive life (28), and significant health care costs are associated with management of these infections and the resulting complications (31), underscoring the urgent need for an efficacious antichlamydial vaccine.
To this end, multiple vaccination strategies for protection against genital C. trachomatis infection have been evaluated. Immunization with inactivated chlamydial organisms or passive transfer of dendritic cells pulsed ex vivo with inactivated chlamydial elementary bodies has been shown to result in significant degrees of protection against genital C. trachomatis challenge (20, 27). The chlamydial major outer membrane protein (MOMP), which is abundantly expressed on the bacterial surface, has been considered the most likely vaccine candidate and has been extensively studied (31). Recombinant MOMP, MOMP synthetic peptides, DNA vaccines encoding MOMP, and the passive transfer of MOMP-specific monoclonal antibodies have been evaluated and found to be only partially effective in protecting experimental animals from subsequent challenge (5, 11, 18, 19, 22, 36, 38, 39, 50, 53, 59, 60). More recently, refolding of MOMP to achieve the native conformation prior to immunization has been reported to effectively reduce vaginal bacterial shedding and infertility rates in mice after genital chlamydial challenge (37). Immunization with an anti-idiotypic antibody to the chlamydial exolipid antigen has been shown to induce partial protection against genital C. trachomatis challenge (58). Thus, only a limited number of candidate chlamydial antigens have been evaluated to determine their protective efficacies, and the efforts have focused primarily on surface-bound structural antigens. However, the genomic sequence of C. trachomatis indicates the potential of several other novel antigens, either structural or secreted, that have yet to be evaluated experimentally as vaccine candidates (31).
Chlamydial protease-like activity factor (CPAF) is a protein secreted into the host cytosol that degrades major histocompatibility complex transcription factors RFX-5 and USF-1, allowing evasion of immune recognition (61, 62, 63). CPAF also has been shown to degrade keratin-8, possibly allowing expansion of the chlamydial “inclusion” inside cells and the probable spread of the bacterium in the extracellular matrix (16). An active form of CPAF has been shown to be produced during infection with five different species of chlamydiae (17). Chlamydia-seropositive humans exhibit higher titers of serum antibodies against CPAF than against exposed surface proteins (i.e., MOMP and Hsp60), indicating the immunogenic dominance of this secreted protein (47, 48, 49). These results also support the hypothesis that CPAF is important in the chlamydial life cycle and the conclusion that this secreted protein should be evaluated as a potential vaccine candidate.
In this study, we examined the protective efficacy of intranasal (i.n.) immunization with recombinant CPAF (rCPAF) in combination with murine interleukin-12 (IL-12) against genital C. trachomatis mouse pneumonitis (recently designated Chlamydia muridarum) challenge. Intranasal vaccination with rCPAF plus IL-12 (rCPAF+IL-12 vaccination) induced robust cell-mediated and humoral immune responses and significantly reduced the time required for resolution of a genital chlamydial infection. Importantly, rCPAF+IL-12 vaccination reduced the incidence of oviduct dilatation and hydrosalpinx in challenged mice. The protective efficacy of rCPAF+IL-12 vaccination also was shown to be highly dependent on endogenous gamma interferon (IFN-γ) production. Taken together, these results demonstrate for the first time that a secreted chlamydial protein, CPAF, is a viable vaccine candidate that should be considered for induction of efficacious, antichlamydial immunity.
rCPAF and IL-12.
rCPAF encoded by the C. trachomatis serovar L2 genome was cloned and expressed in a bacterial system as described previously (16). Briefly, rCPAF constructs cloned from the C. trachomatis L2 genome with a six-histidine (His) tag were cloned into pBAD vectors and expressed in Escherichia coli with isopropyl-β-d-thiogalactopyranoside (IPTG) as an inducer. The fusion protein was purified using Ni-nitrilotriacetic acid agarose beads (Amersham Biosciences Corp.). The purified rCPAF was identified by Western blot analysis using a monoclonal anti-CPAF antibody (15). CPAF activity was determined by determining the ability to degrade transcription factor RFX-5 in a concentration-dependent fashion, using a cell-free degradation assay, as described previously (61). The purified rCPAF was used as a source of protein for all experiments.
A recombinant BA1 protein (designated HisBA-1) was cloned from the Francisella tularensis genome, similarly expressed with a six-histidine tag, and used as a specificity control in some experiments. Murine recombinant IL-12 was a generous gift from Wyeth (Cambridge, MA).
Bacteria.
Chlamydia muridarum was grown on confluent HeLa cell monolayers. Cells were lysed using a sonicator (Fisher, Pittsburgh, PA), and elementary bodies were purified on Renografin gradients as described previously (64). Aliquots of bacteria were stored at −70°C in sucrose-phosphate-glutamine buffer. For some experiments, C. muridarum stocks were inactivated using UV light as described previously (47).
Mice.
Four-week-old, female BALB/c mice were obtained from Charles River Laboratory (Bar Harbor, ME). Age-matched female BALB/c IFN-γ−/− mice were obtained from Jackson Laboratory (Bar Harbor, ME). Mice were housed and bred at the University of Texas at San Antonio and were given food and water ad libitum. Animal care and experimental procedures were performed in compliance with the Institutional Animal Care and Use Committee guidelines.
Intranasal immunization procedures.
Intranasal immunization was performed as described previously (3). Briefly, mice were anesthetized i.n. with 3% isofluorane using a rodent anesthesia system (Harvard Apparatus, Holliston, MA). Mice were immunized i.n. on day 0 with 15 μg rCPAF dissolved in 25 μl sterile phosphate-buffered saline (PBS). This was accompanied or not accompanied on days −1, 0, and 1 with 0.5 μg of recombinant murine IL-12 (Wyeth, Cambridge, MA) administered intranasally in PBS containing 1% normal mouse serum (NMS). Mice were boosted i.n. with 15 μg rCPAF with or without IL-12 on days 14 and 28. Some mice received only IL-12 in PBS-NMS or only PBS-NMS (no rCPAF vaccine). We determined the dose of rCPAF that provided optimal protection (15 μg/mouse) in previous experiments in which titrating doses of rCPAF (1 to 20 μg/mouse) were evaluated to determine their protective efficacies against genital C. muridarum challenge (data not shown).
Antigen-specific splenocyte recall responses.
Spleens were removed 14 days after primary vaccination, and single-cell suspensions were prepared. Collected cells (106 spleen cells/well) were incubated for 72 h with 1 μg rCPAF per well or with the same concentration of an unrelated antigen (hen egg lysozyme [HEL]), HisBA-1), 105 inclusion-forming units (IFU) of UV-inactivated C. muridarum, or PBS alone in 96-well culture plates. Supernatants were assayed to determine the levels of IFN-γ and IL-4 using BDOptEIA kits (BD Pharmingen, San Diego, CA) according to manufacturer's instructions. Absorbance at 630 nm was determined using a μQuant ELISA microplate reader (BioTek Instruments, Winooski, VT).
Detection of antibody and isotype levels by ELISA.
Ten days following final immunization, animals were bled to obtain serum, or bronchoalveolar lavage (BAL) or vaginal lavage fluids were obtained and analyzed by an enzyme-linked immunosorbent assay (ELISA) as described previously (34). Microtiter plates (96 wells) were coated overnight with 5 μg rCPAF in sodium bicarbonate buffer (pH 9.5). Serial dilutions of serum or undiluted bronchoalveolar lavage fluid or vaginal lavage fluid were added to wells, followed by either goat anti-mouse total immunoglobulin, immunoglobulin G1 (IgG1), IgG2a, IgG2b, IgM, or IgA conjugated to alkaline phosphatase (Southern Biotechnology Associates, Birmingham, AL). After washing, p-nitrophenyl phosphate substrate (Sigma, St. Louis, MO) was added for color development, and the absorbance (optical density) at 405 nm was monitored using a μQuant ELISA microplate reader (BioTek Instruments). Reciprocal serum dilutions corresponding to 50% maximal binding were used to obtain titers. Because of the small amounts of antibody in BAL and vaginal fluids and the large dilution involved in the lavage procedure, these samples were tested undiluted. No binding of immune serum was detected in plates coated with HEL or HisBA-1 or to UV-inactivated C. muridarum.
Vaginal C. muridarum challenge and determination of bacterial shedding.
One month following the final vaccination, 6 to 10 animals were anesthetized using inhalational isofluorane (3%) and challenged intravaginally (i.vag.) with 5 × 104 IFU of C. muridarum in 5 μl of sucrose-phosphate-glutamine buffer. Two doses of depo-provera (Pharmacia Upjohn, Kalamazoo, MI) were injected subcutaneously on days −10 and −3 before challenge. To monitor bacterial shedding, vaginal swabs were obtained on different days after vaginal challenge, as indicated below, and this was followed by plating of the swab material on HeLa cell monolayers grown on culture coverslips. Chlamydial inclusions were detected using a murine anti-Chlamydia genus-specific murine monoclonal primary antibody and goat anti-mouse IgG secondary antibody conjugated to Cy3 plus Hoescht nuclear stain. The average number of inclusions in five random microscopic fields was calculated for each animal for earlier times (until day 12 after challenge), and the average number of inclusions on an entire coverslip was calculated for each animal for later times (days 15 to 30 after challenge); the results were expressed as the average number of inclusions per animal group.
Histology and staining.
Genital tracts were removed from mice at various times after challenge, fixed in 10% neutral formalin, and embedded in paraffin blocks. Serial horizontal sections (5 μm) were prepared and stained using hematoxylin and eosin. Stained sections were visualized using a Zeiss Axioskop 2 Plus research microscope, and images were acquired using an Axiocam digital camera (Zeiss, Thornwood, NY).
Histological scoring.
Sections stained with hematoxylin and eosin were scored in blinded fashion by a trained pathologist using a scoring scheme modified from the scheme described by Rank et al. (43). Dilatation of oviducts was scored as follows: 0, no significant dilatation; 1, mild dilatation of a single cross section of oviduct; 2, one to three dilated cross sections of oviduct; 3, more than three dilated cross sections of oviduct; and 4, confluent pronounced dilatation of oviduct. Cellular parameters (levels of polymorphonuclear leukocytes [PMNs], mononuclear cells, and plasma cells) were individually scored as follows: 0, no significant infiltration; 1, infiltration at a single focus; 2, infiltration at two to four foci; 3, infiltration at more than four foci; and 4, confluent infiltration. The results are expressed below as means ± standard errors of the means for scores from all animals in a group (n = 6 to 8).
Statistical analyses.
For comparison of two groups, the Student t test (for normally distributed values) or the Mann-Whitney rank sum test (for values not distributed normally) was used to compare values for continuous variables. For experiments with four groups of animals, analysis of variance followed by a multiple comparison of means (Kruskall-Wallis test) was used. To analyze differences in the time required for clearance, the Kaplan-Meier test was used. Differences between groups were considered statistically significant if the P values were <0.05. All data shown below are representative of two to five independent experiments, and each experiment was analyzed independently.
Intranasal immunization with rCPAF plus IL-12 induces robust cellular Th1-type immune responses.
It has been reported previously that cell-mediated immunity is a crucial component of protective immunity against Chlamydia (26, 45). Therefore, we examined whether vaccination with rCPAF plus IL-12 induces antigen-specific cell-mediated responses. Mice were vaccinated, and rCPAF-induced cytokine recall responses in splenocytes were analyzed 14 days postvaccination. As shown in Fig. Fig.1A,1A, antigen-specific IFN-γ production was significantly greater (P < 0.05) in spleen cells from rCPAF+IL-12-immunized animals than in spleen cells from mice immunized with rCPAF alone. Conversely, IL-4 production was reduced (P < 0.05) in rCPAF+IL-12-immunized mice compared to rCPAF-immunized animals. Splenocytes from mock-vaccinated (PBS) or IL-12-treated mice did not exhibit detectable cytokine induction. The specificity of the response against rCPAF was shown by the minimal induction of cytokine production in spleen cells stimulated with either HEL, UV-inactivated C. muridarum that did not express CPAF in the metabolically inactive elementary body stage, or an unrelated six-histidine-tagged protein cloned from F. tularensis (HisBA-1). These results indicate that i.n. rCPAF+IL-12 vaccination induces a strong Th1-biased antigen-specific cellular immune response.
FIG. 1.
FIG. 1.
Intranasal rCPAF+IL-12 vaccination induces robust cell-mediated and humoral immune responses. (A) Cytokine recall responses after immunization. Animals (three mice/group) were treated i.n. with rCPAF+IL-12, rCPAF alone, IL-12 alone, or (more ...)
Intranasal rCPAF+IL-12 immunization induces systemic and mucosal antibody responses.
The humoral response to rCPAF immunization was examined on day 40 after the initial i.n. immunization. Intranasal vaccination induced a robust serum antibody response that included rCPAF-specific total antibody, IgG2a, IgG2b, and IgG1 isotypes (Fig. (Fig.1B).1B). Specifically, rCPAF+IL-12-immunized mice exhibited significantly enhanced (P < 0.05) titers of anti-rCPAF total antibody and IgG2a antibody but not of IgG2b and IgG1 antibodies compared to animals vaccinated with rCPAF alone. Since mucosal antibodies are important in protection against pathogens (6, 9, 51, 54, 55), induction of an antibody response at local inductive sites was measured in BAL (Fig. (Fig.1C)1C) and vaginal (Fig. (Fig.1D)1D) fluids collected from immunized animals. rCPAF+IL-12-immunized animals exhibited significantly higher levels (P < 0.05) of anti-rCPAF total antibody, IgG2a, and IgA in BAL fluids than animals immunized with rCPAF alone exhibited (Fig. (Fig.1C).1C). Similarly, the rCPAF-specific total antibody, IgG2a, IgG1, and IgA titers in vaginal fluids of rCPAF+IL-12-vaccinated animals were significantly higher (P < 0.05) than the titers in vaginal fluids of mice that received rCPAF alone (Fig. (Fig.1D).1D). Mock-vaccinated or IL-12-treated animals did not exhibit antigen-specific antibody responses in the serum or in respiratory and vaginal fluids. The serum antibody levels on days 14 and 28 (data not shown) exhibited comparable trends, with increased titers of specific antibodies in rCPAF+IL-12-treated animals, although the titers were lower than the titers at 40 days after the first immunization. Furthermore, no serum antibody responses against HEL, HisBA-1, or UV-inactivated C. muridarum were found in any treatment group, clearly indicating the specificity of the immune responses generated by rCPAF+IL-12 vaccination (data not shown). The fact that rCPAF+IL-12-vaccinated animals displayed negligible cell-mediated and humoral cross-reactivity with HisBA-1 indicated that the six-His tag did not contribute to the immunogenicity of rCPAF. These results indicate that rCPAF+IL-12 induces a robust, systemic, and mucosal anti-rCPAF antibody response, including production of antigen-specific IgA at mucosal sites.
rCPAF+IL-12 immunization enhances the resolution of a genital C. muridarum infection.
The protective efficacy of i.n. rCPAF vaccination was examined by monitoring the shedding of chlamydiae after intravaginal challenge with 5 × 104 IFU C. muridarum. As shown in Fig. Fig.2A,2A, there was a significant reduction (≥0.5 log) in the number of chlamydiae recovered from animals vaccinated with rCPAF+IL-12 as early as 8 days postchallenge compared to the number of chlamydiae recovered from mock-immunized (PBS) or IL-12-treated animals. Moreover, 30% of the rCPAF+IL-12-vaccinated animals had successfully resolved the infection by day 12, 80% of the animals had successfully resolved the infection by day 15, and 100% of the animals had successfully resolved the infection by day 18 (Table (Table1).1). In contrast, mock-vaccinated (PBS) animals or animals that received rCPAF or IL-12 alone were still heavily infected at day 15 (Fig. (Fig.2A).2A). Forty percent of the mice vaccinated with rCPAF alone had resolved the infection by day 18 after challenge, and 70% had resolved the infection by day 24 after challenge (Table (Table1).1). In comparison, 30% of mice treated with PBS or IL-12 alone were still actively shedding chlamydiae 30 days after the bacterial challenge. These results demonstrate the efficacy of rCPAF+IL-12 vaccination for enhancing the resolution of a genital chlamydial infection.
FIG. 2.
FIG. 2.
rCPAF+IL-12 vaccination enhances the resolution of a genital challenge. Animals (10 mice/group) were treated with three doses of rCPAF+IL-12, rCPAF, IL-12, or PBS (Mock). One month following the final vaccination, mice were challenged (more ...)
TABLE 1.
TABLE 1.
Percentage of immunized animals shedding Chlamydia after genital challengea
rCPAF+IL-12 vaccination induces protection against C. muridarum-induced upper genital tract pathology.
To determine the effect of rCPAF+IL-12 vaccination on the development of inflammatory disease, gross and histopathological changes in the oviduct and mesosalpingeal tissues were monitored following C. muridarum challenge. Since rCPAF+IL-12 immunization exhibited the greatest efficacy for resolution of genital chlamydial infection (Fig. (Fig.2A2A and Table Table1),1), the C. muridarum-induced pathology of rCPAF+IL-12-vaccinated animals and the C. muridarum-induced pathology of mock-vaccinated (PBS) animals were compared. Genital C. muridarum infections in BALB/c mice have been shown to characteristically induce development of hydrosalpinx as a gross pathological complication (31). As shown in Fig. Fig.3A,3A, gross examination on day 80 postchallenge showed that hydrosalpinx was present in oviducts of mock-vaccinated (PBS) animals (Fig. (Fig.3A,3A, upper panel), compared to the apparent normal appearance in rCPAF+IL-12-immunized mice (3A, lower panel). Specifically, at 50 and 80 days postchallenge, hydrosalpinx was not apparent in any of the rCPAF+IL-12-immunized mice, whereas most (88% and 75%, respectively) of the mock-immunized mice exhibited this gross pathological finding (Table (Table2).2). The observed pathology was bilateral (62.5%) in most mock-immunized (PBS) animals, but it was unilateral in some mock-immunized (PBS) animals at day 50 (25% of the mice) and day 80 (12.5%) after challenge. Hydrosalpinx was not apparent in the mice until day 30 after challenge. Mice treated with IL-12 alone and challenged with C. muridarum had a frequency of hydrosalpinx development similar to that of challenged PBS-treated (mock-immunized) animals (data not shown).
FIG. 3.
FIG. 3.
rCPAF+IL-12 immunization reduces the development of oviduct pathology. Animals (eight mice/group) were immunized with three doses of rCPAF+IL-12 or PBS (Mock), rested for 1 month, and subsequently challenged i.vag. with 5 × 10 (more ...)
TABLE 2.
TABLE 2.
rCPAF+IL-12 immunization reduces the development of hydrosalpinxa
Detailed histopathological comparisons of rCPAF+IL-12- and mock-immunized (PBS) animals after genital C. muridarum challenge were also performed. While most of the rCPAF+IL-12-immunized mice (Fig. (Fig.3B)3B) had apparently normal oviducts, mock-immunized (PBS) animals developed characteristic dilated oviducts (Fig. (Fig.3B)3B) by day 80 after challenge. In addition, there were normal-appearing fimbriae in rCPAF+IL-12-immunized animals, while mock-vaccinated animals exhibited fimbrial flattening. Tissue sections from individual mice in both groups were blind scored by a trained pathologist in order to evaluate the degree of oviduct dilatation. As shown in Fig. Fig.3C,3C, the scores for oviduct dilatation on days 50 and 80 postchallenge in rCPAF+IL-12-vaccinated mice (0.2 ± 0.2 and 0.3 ± 0.18, respectively) were significantly lower than the scores for mock-immunized (PBS) animals (2.3 ± 0.75 and 3.2 ± 0.4, respectively). Very little oviduct dilatation was detected in either group until day 30 after challenge. In addition, Masson trichrome staining of tissues revealed significantly reduced fibrosis in rCPAF+IL-12-immunized animals compared to the fibrosis in mock-immunized animals on day 80 postchallenge (Fig. (Fig.3C3C).
The infiltration of inflammatory cells into the oviduct and mesosalpingeal tissues also was scored and evaluated for rCPAF+IL-12- and PBS-immunized mice on various days after challenge (Fig. (Fig.3D).3D). These analyses revealed that the numbers of PMNs in tissues from the two groups of animals were comparable up to day 18 after challenge. However, on days 30 and 50 after challenge, the scores for the PMN infiltrates in rCPAF+IL-12-vaccinated mice were significantly reduced (0.12 ± 0.1 and 0.1 ± 0.1, respectively) compared to the scores for the mock-immunized (PBS) animals (1.56 ± 0.17 and 1.6 ± 0.18, respectively). No significant PMN infiltration was detected in either group on day 80 postchallenge. The numbers of infiltrating mononuclear and plasma cells in rCPAF+IL-12-immunized animals also were significantly reduced compared to the numbers of these cells in mock-immunized animals from day 18 to day 80 postchallenge (Fig. (Fig.3D).3D). Mice treated with IL-12 alone displayed degrees of oviduct dilatation and cellular infiltration similar to the degrees observed for challenged PBS-treated animals, whereas nonchallenged PBS-treated animals did not exhibit pathological changes at any of the observation times (data not shown). These results demonstrate that rCPAF+IL-12 vaccination reduces the pathology and duration of inflammatory cellular infiltration into the oviduct and mesosalpingeal tissues after genital C. muridarum challenge.
IFN-γ is important in mediating rCPAF+IL-12-induced genital protection.
The role of IFN-γ in rCPAF+IL-12-mediated protection was examined using mice deficient in endogenous IFN-γ production (IFN-γ−/− mice). Vaccinated IFN-γ+/+ mice began resolving the infection as early as 9 days postchallenge (Fig. (Fig.4A4A and Table Table3).3). By 9 and 12 days postchallenge, some vaccinated IFN-γ+/+ mice (33.3% and 50%, respectively) had completely resolved the infection, but no IFN-γ−/− mice (0%) had completely resolved the infection. On day 18 postchallenge, 100% of rCPAF+IL-12-vaccinated IFN-γ+/+ mice had resolved the infection, in contrast to only 16.7% of vaccinated IFN-γ−/− animals. As late as 50 days postchallenge, 50% of vaccinated IFN-γ−/− mice were still shedding low numbers of bacteria. In contrast, mock-immunized IFN-γ+/+ mice completely resolved the infection by day 50 postchallenge, while a majority of similarly treated IFN-γ−/− mice (66.7%) were still shedding chlamydiae 50 days postchallenge, in agreement with previous studies (40). Moreover, the induction of rCPAF-specific antibody responses in vaccinated IFN-γ−/− mice (Fig. (Fig.4B)4B) was comparable to that in similarly treated IFN-γ+/+ mice, suggesting that the absence of IFN-γ in these animals did not completely inhibit development of a humoral immune response after immunization.
FIG. 4.
FIG. 4.
IFN-γ is required for resolution of genital tract infection in rCPAF+IL-12-immunized animals. Groups of IFN-γ+/+ and IFN-γ−/− mice (six mice/group) were immunized with three doses of rCPAF+IL-12 (more ...)
TABLE 3.
TABLE 3.
Percentage of immunized IFN-γ−/− animals shedding Chlamydia after genital challengea
The gross pathology and histopathology of the IFN-γ−/− and IFN-γ+/+ animals were also analyzed on day 80 after challenge. This time was chosen for these analyses based on previously described findings (31) and our previous experiment with BALB/c animals (Fig. (Fig.3),3), in which hydrosalpinx formation was not evident until day 50 after challenge and progressively increased until at least day 80 after challenge. As shown in Table Table4,4, hydrosalpinx was not apparent in rCPAF+IL-12-immunized IFN-γ+/+ mice (0%) but was apparent in similarly treated IFN-γ−/− mice (100% bilateral). Oviduct dilatation also was minimal in rCPAF+IL-12-immunized IFN-γ+/+ mice (scores, 0.9 ± 0.3) compared to similarly treated IFN-γ−/− mice (scores, 3.7 ± 0.33) (Fig. (Fig.5A).5A). All rCPAF+IL-12- and mock-vaccinated (PBS) IFN-γ−/− mice displayed bilateral hydrosalpinx and confluent oviduct dilatation (scores, 3.7 ± 0.3 and 3.8 ± 0.2, respectively), indicating that there was no protective effect in vaccinated IFN-γ−/− animals. Additionally, cellular infiltration into the oviduct and mesosalpingeal tissues was examined on day 80 postchallenge (Fig. (Fig.5B).5B). Fewer mononuclear cells were present in the oviduct and mesosalpingeal tissues of vaccinated IFN-γ+/+ mice (scores, 1.5 ± 0.2) than in the oviduct and mesosalpingeal tissues of similarly treated IFN-γ−/− mice (scores, 2.25 ± 0.36), while both groups had minimal numbers of plasma cells and PMNs in their tissues. The cellular infiltration data for mock-immunized IFN-γ+/+ and IFN-γ−/− mice were comparable. In agreement with the previous experiment with BALB/c mice, rCPAF+IL-12-vaccinated IFN-γ+/+ mice exhibited significantly reduced levels of hydrosalpinx, oviduct dilatation, and mononuclear and plasma cell infiltration compared to the levels in mock-vaccinated (PBS) IFN-γ+/+ animals. These results collectively suggest that rCPAF+IL-12-mediated protection is highly dependent on induction of endogenous IFN-γ production.
TABLE 4.
TABLE 4.
IFN-γ is required for prevention of hydrosalpinx development in Chlamydia-challenged rCPAF+IL-12- immunized animalsa
FIG. 5.
FIG. 5.
IFN-γ is required for prevention of oviduct pathology in Chlamydia-challenged rCPAF+IL-12-immunized animals. Animals (eight mice/group) were immunized with three doses of rCPAF+IL-12 or PBS (Mock), rested for 1 month, and subsequently (more ...)
The incidence of genital chlamydial infection has risen over the last decade despite the availability of potent antimicrobial drugs, underscoring the importance and need for an efficacious vaccine (8). The chlamydial MOMP has been the focus of most current vaccine research. However, MOMP administration results in various degrees of protective immunity and is problematic due to native conformation and protein folding considerations (31, 37). Therefore, identification of other putative vaccine candidates that are used alone or in conjunction with MOMP against genital chlamydial infections is needed. CPAF is a secreted protein of Chlamydia that may be important for intracellular growth, as well as for evading host immune responses (16, 61). Furthermore, Chlamydia-seropositive humans exhibit high titers of anti-CPAF antibodies (47, 48), suggesting that vaccination strategies using CPAF may be beneficial for eliciting protective immunity against Chlamydia. In this study, we showed that i.n. immunization with rCPAF+IL-12 induces a robust Th1 cellular and humoral immune response and leads to accelerated resolution of genital C. muridarum infection in mice. rCPAF+IL-12 vaccination also greatly reduced the incidence of hydrosalpinx and oviduct dilatation, which are complications of genital infection. The protective effects of rCPAF immunization were shown to be highly dependent on endogenous IFN-γ production.
rCPAF+IL-12-immunized mice exhibited significantly reduced vaginal bacterial shedding, beginning as early as 8 days postchallenge, compared to mock-immunized (PBS) animals. In addition, the infection was completely resolved at a significantly (P = 0.0002) earlier time in rCPAF+IL-12-immunized mice (days 12 to 15 postchallenge) than in mock-immunized animals (days 24 to 30 postchallenge). The fact that the resolution in rCPAF+IL-12-vaccinated animals was faster but the animals were not resistant to infection suggests that cellular immunity, not neutralizing antibodies, may be important in mediating the protection. In this study, splenocytes from rCPAF+IL-12-immunized mice exhibited increased IFN-γ production along with concurrent minimal IL-4 production following in vitro rCPAF stimulation. Importantly, the protective effects of rCPAF+IL-12 vaccination were highly dependent on endogenous IFN-γ production. Specifically, vaccinated IFN-γ+/+ mice exhibited reduced bacterial shedding (≥0.5 log) as early as 3 days postchallenge and at all subsequent times compared to the bacterial shedding in similarly treated IFN-γ−/− animals. Vaccinated IFN-γ+/+ mice completely resolved the infection by day 15 postchallenge, whereas resolution was significantly delayed in vaccinated IFN-γ−/− animals, with 50% of the animals still shedding chlamydiae as late as 50 days postchallenge. Thus, despite relatively small differences in the bacterial burden early in the course of infection (until day 12 after challenge), vaccinated IFN-γ+/+ mice exhibited accelerated resolution of infection (P < 0.0001) at later times (days 12 and 15) than similarly treated IFN-γ−/− animals (day 30 or later). These findings are consistent with previous findings showing that early C. muridarum infection in mice is relatively insensitive to the effects of IFN-γ, whereas complete resolution and prevention of dissemination are highly dependent on the effects of this cytokine (12, 23, 24, 40, 44). IFN-γ has a variety of immunoregulatory functions, including induction of Th1 cell differentiation, activation of NK cells, and induction of isotype switching to IgG2a antibody production (7). Specifically, IFN-γ is an essential component of defenses against Chlamydia and is required for resolution of genital infection (12, 23, 24, 40, 44). The bactericidal effect of IFN-γ on Chlamydia-infected cells in vitro has been demonstrated to occur via separate host-specific mechanisms involving indoleamine dioxygenase in human cells and p47 GTPases in murine cells (35).
Intranasal rCPAF vaccination also induced a robust humoral response in systemic and mucosal compartments and specifically increased the levels of anti-CPAF IgG2a and IgA. Since CPAF may be important for evasion of immune recognition, neutralization of its activity may be beneficial to the host. To this end, Sharma et al. (47, 48) identified high titers of anti-CPAF antibody in Chlamydia-seropositive humans, including antibodies that neutralize the proteolytic activity of CPAF. Such neutralizing antibodies against CPAF have yet to be identified in mice. Moreover, CPAF+IL-12-vaccinated B-cell-deficient mice were able to resolve a genital chlamydial infection (A. Murthy and B. Arulanandam, unpublished observations), suggesting that humoral responses may not be absolutely required for CPAF-mediated protective immunity. However, an important role for B cells, antibodies, and Fc receptors (FcR) has been demonstrated for resolution of secondary chlamydial genital infections but not for resolution of primary chlamydial genital infections (29, 32, 33, 42). Antichlamydial IgG2a and IgA antibodies also have been shown to act on FcR+/+ dendritic cells but not on FcR−/− dendritic cells in vitro, enhancing the activation of Th1 responses (30). Additionally, the passive transfer of monoclonal IgA against MOMP has been shown to enhance resistance and to reduce the intensity and duration of C. muridarum infection (47). Therefore, humoral immunity may play an underappreciated role in protective immunity against chlamydial infection.
Although resolution of infection is an important component of an effective antichlamydial vaccine, the principal issue with chlamydial infections is the development of pelvic inflammatory disease and complications such as ectopic pregnancy and infertility. In our study, the incidence of hydrosalpinx and dilatation of oviducts after i.vag. C. muridarum challenge was significantly reduced in rCPAF+IL-12-vaccinated mice compared to mock-immunized animals. Challenged rCPAF+IL-12-vaccinated mice also exhibited significantly lower levels of fibrosis than mock-immunized animals. The mechanical obstruction caused by the ensuing fibrosis and toxic effects of the hydrosalpinx fluid on the ovum have been implicated in the development of infertility (1, 2, 46). The earlier resolution of infection in rCPAF+IL-12-vaccinated animals (days 12 to 15 after challenge) than in mock-immunized (PBS) animals (day 30 after challenge) could account for the significant prevention of pathological consequences. Thus, 14-day doxycycline therapy has been shown to completely prevent the development of hydrosalpinx in C. muridarum-infected mice when treatment was initiated on days 0, 3, and 7 postchallenge but not when treatment was initiated on day 10 postchallenge (52), indicating the effect of an extended bacterial load on pathological consequences. In addition, hydrosalpinx was not apparent in vaccinated IFN-γ+/+ mice (none of six animals examined) but was apparent in vaccinated IFN-γ−/− animals (all six animals examined; bilateral). Also, the incidence of fibrosis was significantly lower in vaccinated IFN-γ+/+ animals than in vaccinated IFN-γ−/− animals. Thus, IFN-γ has been shown to limit excessive inflammatory pathology associated with intracellular bacterial infections (10). Therefore, vaccination-induced antigen-specific IFN-γ responses not only are important for resolution of infection but also are an essential component of protective immunity against disease pathology.
rCPAF+IL-12-vaccinated animals also had lower frequencies of PMNs, mononuclear cells, and plasma cells after genital chlamydial challenge than mock-immunized (PBS) animals had. Notably, at days 30 and 50 postchallenge, the number of infiltrating PMNs was lower in rCPAF+IL-12-immunized mice than in mock-immunized (PBS) animals. Neutrophil-generated inflammatory products, such as matrix metalloproteinase-9, have been implicated in the development of oviduct pathology and infertility (4, 25, 41). Therefore, reduction of PMN infiltration into the oviductal and mesosalpingeal tissues at an earlier point during the course of chlamydial infection also might account for the observed protection against upper genital tract pathology in vaccinated mice. The protection against pathological events in rCPAF+IL-12-vaccinated animals provides only indirect evidence in support of preservation of fertility. Determination of oviduct patency and fertility studies are necessary to determine the reproductive outcome of this vaccination regimen. Additionally, differences in mouse strains have been shown to affect the pathological outcome of genital chlamydial infections (14). Since this study was restricted to BALB/c mice, further studies using mice having different genetic backgrounds and this vaccination regimen are needed.
An important observation from our study is that immunization with recombinant CPAF from C. trachomatis serovar L2 provided protection against C. muridarum challenge. In fact, the amino acid sequences of CPAF from serovar L2 and C. muridarum exhibit significant (82%) identity (17). In addition, monoclonal antibodies raised against serovar L2 CPAF have been shown to recognize CPAF from either serovar L2 or C. muridarum (17), indicating that there is a high degree of immunological cross-reactivity. We also have recently detected CPAF in situ by immunohistochemistry within C. muridarum-infected genital tract epithelial cells using polyclonal mouse immune serum generated against CPAF from serovar L2 (Murthy and Arulanandam, unpublished observations). Together, these results suggest the likelihood of a conserved epitope(s) on CPAF that is involved in protective immunity. Since there are 15 serovars of C. trachomatis that affect humans, a vaccine that provides cross-protection against multiple serovars would be beneficial. MOMP vaccines are homotypic and may not be ideal candidates (31), while the recently identified C. trachomatis polymorphic membrane protein-D is a species-common pan-neutralizing antigen and thus may also be a strong candidate to achieve broad-spectrum protection against chlamydial infections (13).
To our knowledge, here we provide the first evidence of an effective vaccination strategy using a secreted protein from Chlamydia. Contrary to the popular belief that a surface-exposed chlamydial protein would be an ideal vaccine candidate, we have demonstrated that CPAF, a secreted protein, can generate significant immune protection against genital chlamydial challenge. Intracellular bacteria, such as Chlamydia and Mycobacterium, are confined within the phagosome and physically exclude structural components from host immune recognition. However, products such as CPAF are secreted into the host cytosol and presumably escape into the extracellular compartment by exocytosis or upon rupture of infected cells. Therefore, CPAF should be readily available for processing and antigen presentation to CD4+ T cells via the major histocompatibility complex class II pathway. This conclusion is supported by the fact that intraperitoneal anti-CD4+ antibody treatment abrogates the protective effects of rCPAF+IL-12 vaccination (33a). A similar approach using bacillus Calmette-Guérin (Mycobacterium bovis BCG) expressing the Mycobacterium tuberculosis 30-kDa major secretory protein has been shown to induce more robust protective immunity than BCG alone induces against subsequent challenge with virulent organisms (21). The results of our study provide further support for using secreted products as candidate vaccines for intracellular bacteria.
Acknowledgments
This work was supported by National Institutes of Health grants AR048973 and GM08194.
We gratefully acknowledge Neal Guentzel for reviewing the manuscript.
Notes
Editor: F. C. Fang
Footnotes
[down-pointing small open triangle]Published ahead of print on 21 November 2006.
1. Ajonuma, L. C., H. C. Chan, and C. J. Haines. 2001. Hydrosalpinx fluid and in vitro mouse embryo development. J. Obstet. Gynaecol. Res. 27:237-240. [PubMed]
2. Ajonuma, L. C., E. H. Ng, and H. C. Chan. 2002. New insights into the mechanisms underlying hydrosalpinx fluid formation and its adverse effect on IVF outcome. Hum. Reprod. Update 8:255-264. [PubMed]
3. Arulanandam, B. P., J. M. Lynch, D. E. Briles, S. Hollingshead, and D. W. Metzger. 2001. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect. Immun. 69:6718-6724. [PMC free article] [PubMed]
4. Ault, K. A., K. A. Kelly, P. E. Ruther, A. A. Izzo, L. S. Izzo, I. M. Sigar, and K. H. Ramsey. 2002. Chlamydia trachomatis enhances the expression of matrix metalloproteinases in an in vitro model of the human fallopian tube infection. Am. J. Obstet. Gynecol. 187:1377-1383. [PubMed]
5. Berry, L. J., D. K. Hickey, K. A. Skelding, S. Bao, A. M. Rendina, P. M. Hansbro, C. M. Gockel, and K. W. Beagley. 2004. Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect. Immun. 72:1019-1028. [PMC free article] [PubMed]
6. Bienenstock, J. 1970. The significance of secretory immunoglobulins. Can. Med. Assoc. J. 103:39-43. [PMC free article] [PubMed]
7. Boehm, U., T. Klamp, M. Groot, and J. C. Howard. 1997. Cellular responses to interferon-gamma. Annu. Rev. Immunol. 15:749-795. [PubMed]
8. Brunham, R. C., and J. Rey-Ladino. 2005. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat. Rev. Immunol. 5:149-161. [PubMed]
9. Chevailler, A., and G. Renier. 1989. Serum and secretory immunoglobulins A. Molecular and cellular aspects of their biosynthesis and function. Ann. Med. Intern. (Paris) 140:299-313. [In French.]
10. Cooper, A. M., L. B. Adams, D. K. Dalton, R. Appelberg, and S. Ehlers. 2002. IFN-gamma and NO in mycobacterial disease: new jobs for old hands. Trends Microbiol. 10:221-226. [PubMed]
11. Cotter, T. W., Q. Meng, Z. L. Shen, Y. X. Zhang, H. Su, and H. D. Caldwell. 1995. Protective efficacy of major outer membrane protein-specific immunoglobulin A (IgA) and IgG monoclonal antibodies in a murine model of Chlamydia trachomatis genital tract infection. Infect. Immun. 63:4704-4714. [PMC free article] [PubMed]
12. Cotter, T. W., K. H. Ramsey, G. S. Miranpuri, C. E. Poulsen, and G. I. Byrne. 1997. Dissemination of Chlamydia trachomatis chronic genital tract infection in gamma interferon gene knockout mice. Infect. Immun. 65:2145-2152. [PMC free article] [PubMed]
13. Crane, D. D., J. H. Carlson, E. R. Fischer, P. Bavoil, R. C. Hsia, C. Tan, C. C. Kuo, and H. D. Caldwell. 2006. Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen. Proc. Natl. Acad. Sci. USA 103:1894-1899. [PubMed]
14. Darville, T., C. W. Andrews, Jr., J. D. Sikes, P. L. Fraley, and R. G. Rank. 2001. Early local cytokine profiles in strains of mice with different outcomes from chlamydial genital tract infection. Infect. Immun. 69:3556-3561. [PMC free article] [PubMed]
15. Dong, F., M. Pirbhai, Y. Zhong, and G. Zhong. 2004. Cleavage-dependent activation of a Chlamydia-secreted protease. Mol. Microbiol. 52:1487-1494. [PubMed]
16. Dong, F., H. Su, Y. Huang, Y. Zhong, and G. Zhong. 2004. Cleavage of host keratin 8 by a Chlamydia-secreted protease. Infect. Immun. 72:3863-3868. [PMC free article] [PubMed]
17. Dong, F., Y. Zhong, B. Arulanandam, and G. Zhong. 2005. Production of a proteolytically active protein, chlamydial protease/proteasome-like activity factor, by five different Chlamydia species. Infect. Immun. 73:1868-1872. [PMC free article] [PubMed]
18. Dong-Ji, Z., X. Yang, C. Shen, H. Lu, A. Murdin, and R. C. Brunham. 2000. Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immune responses. Infect. Immun. 68:3074-3078. [PMC free article] [PubMed]
19. Eko, F. O., Q. He, T. Brown, L. McMillan, G. O. Ifere, G. A. Ananaba, D. Lyn, W. Lubitz, K. L. Kellar, C. M. Black, and J. U. Igietseme. 2004. A novel recombinant multisubunit vaccine against Chlamydia. J. Immunol. 173:3375-3382. [PubMed]
20. Grayston, J. T., and S. P. Wang. 1978. The potential for vaccine against infection of the genital tract with Chlamydia trachomatis. Sex. Transm. Dis. 5:73-77. [PubMed]
21. Horwitz, M. A., G. Harth, B. J. Dillon, and S. Maslesa-Galic. 2006. A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG. Vaccine 24:1593-1600. [PubMed]
22. Igietseme, J. U., and A. Murdin. 2000. Induction of protective immunity against Chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein-lipophilic immune response-stimulating complexes. Infect. Immun. 68:6798-6806. [PMC free article] [PubMed]
23. Ito, J. I., and J. M. Lyons. 1999. Role of gamma interferon in controlling murine chlamydial genital tract infection. Infect. Immun. 67:5518-5521. [PMC free article] [PubMed]
24. Johansson, M., K. Schon, M. Ward, and N. Lycke. 1997. Genital tract infection with Chlamydia trachomatis fails to induce protective immunity in gamma interferon receptor-deficient mice despite a strong local immunoglobulin A response. Infect. Immun. 65:1032-1044. [PMC free article] [PubMed]
25. Kelly, K. A. 2003. Cellular immunity and Chlamydia genital infection: induction, recruitment, and effector mechanisms. Int. Rev. Immunol. 22:3-41. [PubMed]
26. Landers, D. V., K. Erlich, M. Sung, and J. Schachter. 1991. Role of L3T4-bearing T-cell populations in experimental murine chlamydial salpingitis. Infect. Immun. 59:3774-3777. [PMC free article] [PubMed]
27. Lu, H., and G. Zhong. 1999. Interleukin-12 production is required for chlamydial antigen-pulsed dendritic cells to induce protection against live Chlamydia trachomatis infection. Infect. Immun. 67:1763-1769. [PMC free article] [PubMed]
28. Miller, W. C., C. A. Ford, M. Morris, M. S. Handcock, J. L. Schmitz, M. M. Hobbs, M. S. Cohen, K. M. Harris, and J. R. Udry. 2004. Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA 291:2229-2236. [PubMed]
29. Moore, T., G. A. Ananaba, J. Bolier, S. Bowers, T. Belay, F. O. Eko, and J. U. Igietseme. 2002. Fc receptor regulation of protective immunity against Chlamydia trachomatis. Immunology 105:213-221. [PubMed]
30. Moore, T., C. O. Ekworomadu, F. O. Eko, L. MacMillan, K. Ramey, G. A. Ananaba, J. W. Patrickson, P. R. Nagappan, D. Lyn, C. M. Black, and J. U. Igietseme. 2003. Fc receptor-mediated antibody regulation of T cell immunity against intracellular pathogens. J. Infect. Dis. 188:617-624. [PubMed]
31. Morrison, R. P., and H. D. Caldwell. 2002. Immunity to murine chlamydial genital infection. Infect. Immun. 70:2741-2751. [PMC free article] [PubMed]
32. Morrison, S. G., and R. P. Morrison. 2001. Resolution of secondary Chlamydia trachomatis genital tract infection in immune mice with depletion of both CD4+ and CD8+ T cells. Infect. Immun. 69:2643-2649. [PMC free article] [PubMed]
33. Morrison, S. G., H. Su, H. D. Caldwell, and R. P. Morrison. 2000. Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4+ T cells but not CD8+ T cells. Infect. Immun. 68:6979-6987. [PMC free article] [PubMed]
33a. Murphey, C., A. K. Murthy, P. A. Meier, M. N. Guentzel, G. Zhong, and B. P. Arulanandam. The protective efficacy of chlamydial protease-like activity factor vaccination is dependent upon CD4+ T cells. Cell. Immunol, in press.
34. Murthy, A. K., J. Sharma, J. J. Coalson, G. Zhong, and B. P. Arulanandam. 2004. Chlamydia trachomatis pulmonary infection induces greater inflammatory pathology in immunoglobulin A deficient mice. Cell. Immunol. 230:56-64. [PubMed]
35. Nelson, D. E., D. P. Virok, H. Wood, C. Roshick, R. M. Johnson, W. M. Whitmire, D. D. Crane, O. Steele-Mortimer, L. Kari, G. McClarty, and H. D. Caldwell. 2005. Chlamydial IFN-gamma immune evasion is linked to host infection tropism. Proc. Natl. Acad. Sci. USA 102:10658-10663. [PubMed]
36. Pal, S., K. M. Barnhart, Q. Wei, A. M. Abai, E. M. Peterson, and L. M. de la Maza. 1999. Vaccination of mice with DNA plasmids coding for the Chlamydia trachomatis major outer membrane protein elicits an immune response but fails to protect against a genital challenge. Vaccine 17:459-465. [PubMed]
37. Pal, S., E. M. Peterson, and L. M. de la Maza. 2005. Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria. Infect. Immun. 73:8153-8160. [PMC free article] [PubMed]
38. Pal, S., I. Theodor, E. M. Peterson, and L. M. de la Maza. 1997. Immunization with an acellular vaccine consisting of the outer membrane complex of Chlamydia trachomatis induces protection against a genital challenge. Infect. Immun. 65:3361-3369. [PMC free article] [PubMed]
39. Pal, S., I. Theodor, E. M. Peterson, and L. M. de la Maza. 1997. Monoclonal immunoglobulin A antibody to the major outer membrane protein of the Chlamydia trachomatis mouse pneumonitis biovar protects mice against a chlamydial genital challenge. Vaccine 15:575-582. [PubMed]
40. Perry, L. L., K. Feilzer, and H. D. Caldwell. 1997. Immunity to Chlamydia trachomatis is mediated by T helper 1 cells through IFN-gamma-dependent and -independent pathways. J. Immunol. 158:3344-3352. [PubMed]
41. Ramsey, K. H., I. M. Sigar, J. H. Schripsema, N. Shaba, and K. P. Cohoon. 2005. Expression of matrix metalloproteinases subsequent to urogenital Chlamydia muridarum infection of mice. Infect. Immun. 73:6962-6973. [PMC free article] [PubMed]
42. Ramsey, K. H., L. S. Soderberg, and R. G. Rank. 1988. Resolution of chlamydial genital infection in B-cell-deficient mice and immunity to reinfection. Infect. Immun. 56:1320-1325. [PMC free article] [PubMed]
43. Rank, R. G. 1994. Animal models for urogenital infections. Methods Enzymol. 235:83-93. [PubMed]
44. Rank, R. G., K. H. Ramsey, E. A. Pack, and D. M. Williams. 1992. Effect of gamma interferon on resolution of murine chlamydial genital infection. Infect. Immun. 60:4427-4429. [PMC free article] [PubMed]
45. Rank, R. G., L. S. Soderberg, and A. L. Barron. 1985. Chronic chlamydial genital infection in congenitally athymic nude mice. Infect. Immun. 48:847-849. [PMC free article] [PubMed]
46. Shah, A. A., J. H. Schripsema, M. T. Imtiaz, I. M. Sigar, J. Kasimos, P. G. Matos, S. Inouye, and K. H. Ramsey. 2005. Histopathologic changes related to fibrotic oviduct occlusion after genital tract infection of mice with Chlamydia muridarum. Sex. Transm. Dis. 32:49-56. [PubMed]
47. Sharma, J., A. M. Bosnic, J. M. Piper, and G. Zhong. 2004. Human antibody responses to a Chlamydia-secreted protease factor. Infect. Immun. 72:7164-7171. [PMC free article] [PubMed]
48. Sharma, J., F. Dong, M. Pirbhai, and G. Zhong. 2005. Inhibition of proteolytic activity of a chlamydial proteasome/protease-like activity factor by antibodies from humans infected with Chlamydia trachomatis. Infect. Immun. 73:4414-4419. [PMC free article] [PubMed]
49. Sharma, J., Y. Zhong, F. Dong, J. M. Piper, G. Wang, and G. Zhong. 2006. Profiling of human antibody responses to Chlamydia trachomatis urogenital tract infection using microplates arrayed with 156 chlamydial fusion proteins. Infect. Immun. 74:1490-1499. [PMC free article] [PubMed]
50. Skelding, K. A., D. K. Hickey, J. C. Horvat, S. Bao, K. G. Roberts, J. M. Finnie, P. M. Hansbro, and K. W. Beagley. 2006. Comparison of intranasal and transcutaneous immunization for induction of protective immunity against Chlamydia muridarum respiratory tract infection. Vaccine 24:355-366. [PubMed]
51. Stefani, D. V. 1973. Secretory immunoglobulins and the problem of local immunity (literature review). Zh. Mikrobiol. Epidemiol. Immunobiol. 50:7-11. [In Russian.]
52. Su, H., R. Morrison, R. Messer, W. Whitmire, S. Hughes, and H. D. Caldwell. 1999. The effect of doxycycline treatment on the development of protective immunity in a murine model of chlamydial genital infection. J. Infect. Dis. 180:1252-1258. [PubMed]
53. Su, H., M. Parnell, and H. D. Caldwell. 1995. Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: serum neutralizing IgG antibodies do not protect against chlamydial genital tract infection. Vaccine 13:1023-1032. [PubMed]
54. Thomasi, T. B., Jr. 1972. Secretory immunoglobulins. N. Engl. J. Med. 287:500-506. [PubMed]
55. Tomasi, T. B., Jr., and J. Bienenstock. 1968. Secretory immunoglobulins. Adv. Immunol. 9:1-96. [PubMed]
56. Westrom, L., R. Joesoef, G. Reynolds, A. Hagdu, and S. E. Thompson. 1992. Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex. Transm. Dis. 19:185-192. [PubMed]
57. Westrom, L., and P. A. Mardh. 1983. Chlamydial salpingitis. Br. Med. Bull. 39:145-150. [PubMed]
58. Whittum-Hudson, J. A., D. Rudy, H. Gerard, G. Vora, E. Davis, P. K. Haller, S. M. Prattis, A. P. Hudson, W. M. Saltzman, and E. S. Stuart. 2001. The anti-idiotypic antibody to chlamydial glycolipid exoantigen (GLXA) protects mice against genital infection with a human biovar of Chlamydia trachomatis. Vaccine 19:4061-4071. [PubMed]
59. Zhang, D., X. Yang, J. Berry, C. Shen, G. McClarty, and R. C. Brunham. 1997. DNA vaccination with the major outer-membrane protein gene induces acquired immunity to Chlamydia trachomatis (mouse pneumonitis) infection. J. Infect. Dis. 176:1035-1040. [PubMed]
60. Zhang, D. J., X. Yang, C. Shen, and R. C. Brunham. 1999. Characterization of immune responses following intramuscular DNA immunization with the MOMP gene of Chlamydia trachomatis mouse pneumonitis strain. Immunology 96:314-321. [PubMed]
61. Zhong, G., P. Fan, H. Ji, F. Dong, and Y. Huang. 2001. Identification of a chlamydial protease-like activity factor responsible for the degradation of host transcription factors. J. Exp. Med. 193:935-942. [PMC free article] [PubMed]
62. Zhong, G., T. Fan, and L. Liu. 1999. Chlamydia inhibits interferon gamma-inducible major histocompatibility complex class II expression by degradation of upstream stimulatory factor 1. J. Exp. Med. 189:1931-1938. [PMC free article] [PubMed]
63. Zhong, G., L. Liu, T. Fan, P. Fan, and H. Ji. 2000. Degradation of transcription factor RFX5 during the inhibition of both constitutive and interferon gamma-inducible major histocompatibility complex class I expression in Chlamydia-infected cells. J. Exp. Med. 191:1525-1534. [PMC free article] [PubMed]
64. Zhong, G. M., R. E. Reid, and R. C. Brunham. 1990. Mapping antigenic sites on the major outer membrane protein of Chlamydia trachomatis with synthetic peptides. Infect. Immun. 58:1450-1455. [PMC free article] [PubMed]
Articles from Infection and Immunity are provided here courtesy of
American Society for Microbiology (ASM)